Oramed Pharm ( (ORMP) ) just unveiled an update.
On April 28, 2025, Oramed Pharmaceuticals announced a strategic investment of $36.9 million in Alpha Tau Medical, marking a significant collaboration between the two companies. This partnership aims to accelerate the commercialization of Alpha Tau’s innovative alpha-radiation cancer therapy, Alpha DaRT®, by leveraging Oramed’s expertise in capital markets and strategic guidance. The collaboration includes a three-year service agreement and the appointment of two Oramed directors to Alpha Tau’s board, aligning with Oramed’s strategy to expand its footprint in therapeutic delivery technologies.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
Oramed Pharm’s overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals is a platform technology pioneer specializing in oral delivery solutions for drugs traditionally administered via injection. The company utilizes its novel Protein Oral Delivery (POD™) technology to enhance drug integrity and absorption, with operations based in the United States and Israel.
YTD Price Performance: -3.32%
Average Trading Volume: 239,318
Technical Sentiment Signal: Buy
Current Market Cap: $95.18M
See more insights into ORMP stock on TipRanks’ Stock Analysis page.